Resources

Louis Kuritzky, MD; Benjamin J. Epstein, PharmD, BCPS; and Frank Lavernia, MD Abstract: Good control of diabetes provides meaningful microvascular risk reduction; yet, patients with type 2 diabetes mellitus commonly languish at unsatisfactory levels of glycated hemoglobin (HbA1c) for protracted periods. A variety of factors contribute to this clinical inertia, as …

Frank Lavernia, MD Abstract: Objective This article describes a patient with type 2 diabetes mellitus achieving glycemic control after transitioning from premixed to basal-prandial insulin.

Daniel A. Nadeau, MD Abstract: The prevalence of type 2 diabetes mellitus has reached epidemic proportions. Current treatment options for patients with diabetes include lifestyle modifications (eg, diet and exercise) along with pharmacotherapy (eg, oral antidiabetic drugs [OADs], incretin-based therapies, and insulin). Despite the availability of effective and safe treatments, …

iBGStar iPhone diabetes device Sanofi-Aventis launched its iBGStar hybrid medical device to monitor blood glucose levels that can also be plugged into an iPhone or an iPod touch. The iBGStar is a USB-sized blood glucose monitor that works as a standalone monitor, or it can be used with the new iBGStar …

Adding exenatide to insulin glargine for patients who aren’t fully controlled with insulin glargine and/or other oral agents can help to improve their blood glucose….

Early treatment of screen-detected Type 2 diabetes works regardless of how intensively glucose, lipids, and blood pressure are managed, experts concluded on the basis of a large randomized trial presented…. 

Continuous blood glucose monitors may not accurately detect low blood sugar, researchers found….

Patients with Type 1 diabetes who have repeated episodes of hypoglycemia appear to be at risk for early signs of atherosclerosis, researchers said….

Adding 50 mg of sitagliptin (Januvia) to pioglitazone (Actos) allowed patients with Type 2 diabetes to achieve sustained glycemic control, a yearlong trial showed….

Farnesoid X receptor agonists, 11-β-HSD1 inhibitors, and glucokinase activators are some of the new approaches to treating Type 2 diabetes described in research presented, but some senior researchers expressed doubts about the clinical need for them….